Cryosite Limited
Cryosite Limited
Your view on CTE.AX
Overview
What the company does, where it operates, and who runs it.
About Cryosite Limited
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Jane Hao
- Headquarters
- 13a Ferndell Street, South Granville, NSW, AU
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Jane Hao
- Headquarters
- 13a Ferndell Street, South Granville, NSW, AU
Cryosite Limited, founded in 1999 and headquartered in South Granville, Australia, specializes in providing outsourced logistics and storage solutions to the life sciences industry within Australia. The company operates through two distinct divisions. Its Clinical Trials and Biological Services Logistics segment offers comprehensive support to the clinical research and pharmaceutical sectors, encompassing services such as specialized temperature-controlled and general biological storage, precise labeling, secondary packaging, and end-to-end supply chain management capabilities like scheduled drug distribution, returns processing, material destruction, status oversight, comparator sourcing, and validated import/export and transportation. The second division, Cord Blood and Tissues Storage, focuses on the long-term cryogenic preservation of cord blood and tissue samples. Cryosite's client base spans the research, medical, pharmaceutical, veterinary, and biotechnology industries.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Cryosite Limited, and the rating behind it. CTE.AX last traded at AUD 1.20, 28.5× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Cryosite Limited. Starting points for Cryosite Limited: P/E 28.5, EPS AUD 0.04, beta 0.16 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Cryosite Limited. Cryosite Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Cryosite Limited. Trailing twelve-month EPS for Cryosite Limited stands at AUD 0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Cryosite Limited. Cryosite Limited has reported as a listed company since 2002. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Cryosite Limited valued side by side against its closest peers. Cryosite Limited is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Cryosite Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Cryosite Limited executives and directors. Shares of Cryosite Limited have traded between AUD 0.66 and AUD 1.31 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Cryosite Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Cryosite Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Cryosite Limited. Coverage tracks Cryosite Limited within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.